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Botulinum toxin type A and 
acupuncture for masticatory 
myofascial pain: a randomized clinical 
trial
BoNT-A has been widely used for TMD therapy. However, the potential 
benefits compared to dry needling techniques are not clear. Objective: this 
study aimed to compare the immediate effects of botulinum toxin type A 
(BoNT-A) injections and Acupuncture in myofascial temporomandibular 
disorders (TMD) patients. Methodology: 54 women were divided into three 
groups (n=18). AC patients received four sessions of traditional acupuncture, 
being one session/week during 20-min. BoNT-A patients were bilaterally 
injected with 30U and 10U in masseter and anterior temporal muscles, 
respectively. Moreover, a control group received saline solution (SS) in the 
same muscles. Self-perceived pain was assessed by visual analog scale, 
while pressure pain threshold (PPT) was verified by a digital algometer. 
Electromyographic evaluations (EMG) of anterior temporal and masseter 
muscles were also measured. All variables were assessed before and 1-month 
after therapies. The mixed-design two-way repeated measures ANOVA and 
Tukey’s post-hoc tests were used for analysis, considering a=0.05. Results: 
Self-perceived pain decreased in all groups after one month of therapy 
(P<.001). BoNT-A was not better than AC in pain reduction (P=0.05), but both 
therapies were more effective in reducing pain than SS (P<0.05). BoNT-A was 
the only treatment able to improve PPT values (P<0.05); however, a severe 
decrease of EMG activity was also found in this group, which is considered 
an adverse effect. Conclusion: after one month of follow-up, all therapies 
reduced the self-perceived pain in myofascial TMD patients, but only BoNT-A 
enhanced PPT yet decreased EMG.
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Introduction
Myofascial pain (MFP) is a disorder characterized 
by localized muscle tenderness, regional pain, and 
limited range of motion.1 It is the most typical cause 
of persistent regional pain, such as back and shoulder 
pain, tension-type headaches, and facial pain.2 
Furthermore, it is a common condition in dentistry 
with prevalence from 10% to 68% among subjects 
with temporomandibular disorders (TMD).3 
Masticatory myofascial pain (MMFP) has a complex 
pathogenesis expressed by a multifactorial etiology, 
which led to the proposal of numerous conservatives, 
reversible, and minimally invasive therapies to treat 
this condition.4 The needling technique is a minimally 
invasive therapy widely used for MMFP and it can be 
classified as an injection technique (IT), often referred 
to as “wet needling,” and dry needling (DN). While the 
IT deliver pharmacological agents, e.g., anesthetics, 
botulinum toxins or other agents, with needles,5 the 
DN consists in the insertion of thin monofilament 
needles, as the ones used for acupuncture practice, 
without any injectate.6
Acupuncture is a therapeutic method of the 
traditional Chinese medicine which differs from 
conventional DN techniques since needles are not 
inserted just in the painful region. Its antinociceptive 
effects7 include immediate reduction in local, referred, 
and widespread pain,8 and reduction in peripheral and 
central sensitization.5 Although a recent randomized 
clinical trial reported pain reduction of 84% after one 
month of treatment – concluding that acupuncture 
was effective for MMFP pain9, available systematic 
reviews did not find further advantages in the use 
of acupuncture for MMFP over other treatments 
such as oral appliances, behavioral therapy, and/or 
pharmacotherapies.10,11 These controversies might be 
due to several methodological shortcomings, leading 
to inconclusive results, which expose the need for high 
quality studies comparing the efficacy of acupuncture 
with other treatments. 
Botulinum toxin type A (BoNT-A) is an FDA-
approved treatment for some pain disorders (as 
dystonia and migraine), becoming one of the most 
popular IT used to control MFP.4 Animal studies have 
demonstrated that peripheral injections of BoNT-A 
have analgesic effects on pain stages by inhibiting 
the release of nociceptive mediators (peripherally and 
centrally), mechanism independent of its neuromotor 
effect.12,13 Based on this data, BoNT-A has been 
used as an off-label treatment to control MMFP. 
Moreover, a few well-designed clinical trials14,15,16 have 
demonstrated the superiority of this substance over 
placebo, but not over conservative treatments like 
oral appliances.15 Besides, a prospective study showed 
that BoNT-A injections in the masticatory muscles 
are also effective in reducing MMFP and tension-type 
headache, recommending this therapy for muscle 
pain.17 Conversely, the lack of consensus on the effects 
of BoNT-A is due to the number of low-quality studies 
available, and especially to the post-injection adverse 
effects in muscle and bone tissues, being the reason 
why its benefits for MMFP remain unclear.18,19 
Studies comparing DN techniques with BoNT-A 
for myofascial TMD pain are scarce, and no previous 
study compared these treatments with an injection 
placebo group.20-22 Moreover, systematic reviews 
were inconclusive about the effectiveness of needling 
therapy, since it was not possible to determine if the 
technique (dry or wet) or the injectate were responsible 
for the improvements.23 Therefore, this study aims to 
compare the immediate effects of BoNT-A injections 
and acupuncture therapy in  myofascial TMD patients.
Methodology
Experimental design
This randomized single-blinded controlled clinical 
trial, conducted following the Helsinki Declaration, 
was approved by the local Research Ethics Committee 
(CAAE: 22953113.8.0000.5418) and by the Brazilian 
Registry of Clinical Trials (ReBEC RBR-2d4vvv). All 
individuals were informed about the research purposes 
and signed an informed consent form.
The sample size estimation was based on the 
average pain scores of previous studies,14,24 and it 
was performed by using the G*Power 3.1.9.2 software 
(Düsseldorf, Germany). The following parameters 
were considered: a) test power of 0.9; b) 0.05 
significance level; c) effect size of 0.4. Considering 
these standards, 15 participants per group would be 
sufficient to detect statistically significant differences. 
However, considering possible dropouts, 20% was 
added in each group. Thus, the final sample size 
comprised 54 individuals, which were randomly divided 
into three groups: acupuncture (n=18); BoNT-A 
(n=18); and saline solution (SS) (n=18), as a negative 
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control group. For this allocation, a software was 
used (https://random-allocation-software.software.
informer. com/2.0/) and the sequence was sealed in an 
opaque envelope, which was operated by a researcher 
not involved in other procedures of this study. The 
investigator assessing the outcomes was masked to 
the treatment assignments.
The sample was obtained from women seeking 
for TMD treatment at the Piracicaba Dental School, 
University of Campinas, Piracicaba, Brazil, from 2014 
to 2016. Patients had to be female with MMFP, with 
general good health, be aged between 18 and 45 
years, with complete dentition, ongoing conservative 
treatment for at least three months without 30% of pain 
improvement and be using oral contraceptives in order 
to be included in the study. Subjects with systemic 
diseases (arthritis, arthrosis, diabetes), uncontrolled 
hypertension, neurological disorders, positive history 
of trauma in the orofacial and neck area, with dental 
pain, with self-reported sleep bruxism, and taking 
any medication for pain control were excluded from 
the recruitment (Figure 1). The diagnostic of MMFP 
was based on a clinical examination performed 
according to the official Portuguese version of the 
Research Diagnostic Criteria for Temporomandibular 
Disorders (RDC/TMD) – Axis I,25 by two calibrated 
raters (Kappa coefficient = 0.80). To achieve the 54 
volunteers included in the study, 80 female subjects 
were screened for eligibility. Considering the inclusion 
and exclusion criteria, 65 participants were suitable to 
participate. However, before allocation, five individuals 
were excluded since they refused to participate (n=4) 
or to stop previous therapies (n=1). Six additional 
exclusions occurred due to lack of compliance, leading 
to a final sample of 18 volunteers per group (Figure 1).
Therapies
Acupuncture
Acupuncture group received four sessions of 
traditional acupuncture, one session per week, with 
20-min each for one month. The following points were 
selected for this therapy: LI4 (Hegu), LI11 (Quchi), 
SI19 (Tinggong), LR2 (Xingjian), GB20 (Fengchi), 
GB21 (Jianjing), GB34 (Yanglingquan), BL2 (Zanzhu), 
CV23 (Lianquan), and TE23 (Sizhukong).24 Disposable, 
sterile, individually packed, stainless steel needles 
(Huan Qiu; Suzhou Huanqiu Acupuncture Medical 
Appliance Co. Ltd., Suzhou, China) were used for this 
purpose by a acupuncturist. For facial points, needles 
had 0.22 mm of diameter and 13 mm length, and 0.25 
mm diameter and 30 mm length for distal points. The 
needles were manually inserted and rotated in both 
clockwise and counterclockwise directions, until the 
patient related the sensation on needle site or along 
the meridian. 
Botulinum toxin type A (BoNT-A)
BoNT-A (100 U; Botox, Allergan, Irvine, California, 
CA, USA) was reconstituted using non-preserved 
sterile saline solution 0.9%. A single bilateral injection 
Figure 1- Flowchart of participants enrollment
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was applied in the masseter and anterior temporalis 
muscles using 30U and 10U of BoNT-A, respectively15 
by a calibrated researcher, distributed in five sites 
for each muscle. It was used a 1 mL syringe with a 
30-gauge and 13 mm needle. Briefly, for the masseter, 
the injected sites were in the inferior part of the 
muscle (on mandibular angle), 5 mm apart from 
each other. For the anterior temporal muscles, sites 
were determined according to the functional test, 
considering the most prominent part, and must be 1 
cm external to the eyebrow and 5 mm apart among 
them (Figure 2). Injections were performed bilaterally 
regardless the patient had pain in only one side of 
the face.
This injection technique consisted in inserting the 
needle into the soft tissue until reaching the bone; 
then, the needle was slightly moved to place the tip 
inside the muscle. Before injection, a careful aspiration 
was performed to avoid a possible intravascular 
administration. 
Saline Solution (SS)
SS (NaCl 0.9%) was bilaterally injected into the 
same muscles and sites, following the same protocol 
and doses, as described for BoNT-A injections. 
Injections of BoNT-A and SS were performed in a single 
appointment by the same trained clinician, who was 
blinded to the treatment assignment. 
Outcomes
Self-perceived pain: Visual Analog Scale (VAS)
VAS is a 100 mm horizontal line, anchored by 
the words “no pain” at the left end, and “worst 
pain imaginable” at the right end. Participants were 
instructed to mark a line at any point, representing 
the level of current, worst, and average pain of the 
last month. 
Pain sensitivity: Pressure Pain Threshold (PPT) 
PPT was assessed by a digital algometer (Kratos 
DDK-20; São Paulo, Brazil) with 1 cm2 circular flat 
rod, for the bilateral evaluation of the masseter and 
anterior temporal muscles. Patients were instructed 
to indicate the moment when the pressure became 
painful. They were sat in a chair with the Frankfurt 
plane parallel to the ground, and muscles should be 
relaxed. The circular flat rod was perpendicularly 
pressed to the surface skin at a 0.5 kg/cm² rate, 
following the sequence: right anterior temporal, right 
masseter, left masseter, and left anterior temporal 
muscles. After a five-minutes rest, the pressure was 
applied again, as follows: left anterior temporal, right 
anterior temporal, left masseter, and right masseter.
Electromyographic assessment 
The bilateral EMG signals of the anterior temporal 
and the superficial masseter muscles were recorded by 
the ADS 1200 device (Lynx Electronic Technology Ltd, 
Sao Paulo, Brazil), which has eight channels, adjusted 
gain of 1e16,000, band-pass filter of 20e500 Hz and 
sampling frequency of 2000 Hz per channel. A circular 
passive bipolar Ag/AgCl double electrode with 1 cm 
interelectrode distance was used (Hal Ind. Com. Ltda, 
Sao Paulo, Brazil).
Before the recordings, the volunteers’ skin was 
cleaned with cotton and 70% alcohol, and a function 
Figure 2- A, marked points for BoNT-A injection. B, temporal muscle injection; C, masseter muscle injection
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test was performed to identify the center of the muscle 
venter, in which the electrodes should be fixed. The 
reference electrode was placed on the participants’ 
manubrium of the sternum. The electrical activity 
of each muscle was recorded in mandibular postural 
position (rest) and maximum volunteer contraction 
(MVC). Each activity was measured three times, for 
five seconds, with a two minute period of rest between 
them, in order to avoid fatigue. The MVC activity was 
obtained by requiring the patients to chew a piece 
of Parafilm M (American National Can, Chicago, IL, 
USA) that was placed bilaterally in the molar region. 
Participants were instructed to clench their jaw to 
the maximum possible extent, and to maintain the 
pressure for five seconds, as were verbally stimulated 
by the examiner. 
Simultaneous signals were obtained by the software 
Lynx AqDados 7.02 (Lynx Electronic Technology Ltd, 
Sao Paulo, Brazil), and the root mean square (RMS) 
values were processed by the software Lynx AqD 
Analysis 7.0 (Lynx Electronic Technology Ltd, Sao 
Paulo, Brazil). The RMS values of each acquisition were 
considered as those obtained in the 2s and 4s-interval. 
The mean values of the three acquisitions (Rest and 
MI) were considered. 
As the evaluations were carried out in different 
timepoints, an acetate plate was fabricated for each 
patient to standardize the algometer position and the 
electrodes’ placement between sessions. The acetate 
plate followed the anatomic reference lines (external 
angle of the eye, tragus of the ear, and external angle 
of the mandible), and was clipped where the algometer 
and electrodes were placed.
Statistical analysis 
All data for groups and periods were expressed as 
means ± standard deviation (SD) and were assessed 
for normal distribution with the Shapiro-Wilk test. A 
mixed-design repeated measures two-way ANOVA 
test was used to observe the difference among groups 
over time and within the group. The statistical analysis 
compared the results observed before the treatment 
(baseline) with those observed one month after the 
therapies. Moreover, the three groups were compared 
to verify a possible statistically significant difference 
among therapies. The ANOVA test was followed by post 
hoc Tukey’s test. All analyses were performed using 
SPSS for Windows (release 21.0, SPSS Inc.), with a 
5% significance level. 
Results
Participants’ age did not differ among the three 
groups. acupuncture (mean age 30.3±6.9 years); 
BoNT-A (mean age 34.6±6.5 years); and SS (mean 
age 30.8±6.9 years) (P= .124). 
Self-perceived pain (VAS)
Self-perceived pain showed a significant decrease in 
all groups after one-month of therapy (P<.001). When 
comparing the different treatments, improvement in 
pain levels did not significantly differ between the 
acupuncture and BoNT-A groups (P>.05), but both 
groups presented a significant reduction on pain 
compared to the SS group (P<.001) (Figure 3). 
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Figure 3- Self-perceived pain (VAS) values for each group, before and after treatments.
ϯ represent significant differences among groups (P<0.05); * represent significant differences among time points (P<0.05).
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Pain sensitivity (PPT)
Considering the PPT values for the masseter 
muscles, the intragroup evaluation demonstrated that 
the acupuncture and SS groups did not show significant 
improvements (P=.359 and P=.220, respectively) 
after one-month of therapy. Notwithstanding, BoNT-A 
group presented significantly higher PPT values 
(P<.001) after one month of follow-up. Comparisons 
among groups, showed that acupuncture values did 
not differ from SS and BoNT-A (P=.751 and P=.123, 
respectively) groups. On the other hand, BoNT-A 
values were significantly higher than those obtained 
in the SS group (P=.006) (Table 1).
Furthermore, the PPT results for the anterior 
temporal muscles are in accordance with those 
achieve for the masseter muscles. Thus, intragroup 
evaluation showed no improvements on PPT values for 
the acupuncture and SS groups (P=.415 and P=.471, 
respectively), after one month of evaluation. Only 
the BoNT-A group presented statistically significant 
differences from baseline to the first-month follow-
up (P<.001). Intergroup comparisons reveled that 
acupuncture values did not differ from SS (P=1.000) 
and BoNT-A (P=.111) values. However, BoNT-A 
values were statistically significant different just when 
compared with the SS group (P=.016) (Table 1). 
Electromyographic activity (EMG)
The EMG results for both masseter and anterior 
temporal muscles demonstrated that only volunteers 
in the BoNT-A group presented a significant reduction 
of the EMG activity one-month after the treatment 
(P<.001). Intergroup comparisons at the one-month 
follow-up showed a significant decrease in the 
masseter muscle activity in BoNT-A group compared 
to acupuncture (P =.020) and SS (P <.001), and 
these results were also found for the anterior temporal 
muscles (P <.001) (Figure 4).
Discussion
The main findings of this study were that – after 
four weeks – all treatment groups (acupuncture, 
BoNT-A, and SS) were able to significantly reduce 
the self-perceived pain, without differences between 
acupuncture and BoNT-A, while both treatments were 
superior to the SS group. Moreover, considering the 
PPT values for both masseter and anterior temporal 
muscles, only BoNT-A group lead to a significant 
increase in PPT. Likewise, only patients treated with 
BoNT-A showed a significant reduction of the EMG 
activity in both studied muscles.
Pain is considered one of the most common reasons 
for a TMD patient seek treatment.26 All therapies used 
in this research were able to significantly decrease 
Group/PPT-Muscle Baseline 1 Month
Temporal
Acupuncture 0.67 (±0.27)Aa 0.73 (±0.19)Aa
Botulinum Toxin A 0.54 (±0.22)Aa 0.92 (±0.29)Ab
Saline Solution 0.61 (±0.23)Aa 0.66 (±0.33)Aa
Masseter
Acupuncture 0.67 (±0.23)Aa 0.72 (±0.18)Aa
Botulinum Toxin A 0.53 (±0.19)Aa 0.88 (±0.25)Ab
Saline Solution 0.57 (±0.17)Aa 0.64 (±0.25)Aa
Different uppercase letters represent significant differences 
among groups (P<0.05); different lowercase letters denote 
significant differences among assessment time points (P<0.05); 
PPT: Pressure pain threshold; kg/cm2=Kilogram per square 
centimeter.
Table 1- Mean and standard deviation (SD) of pain pressure 
threshold (kg/cm-2) for each group, before and after treatments
Botulinum toxin type A and acupuncture for masticatory myofascial pain: a randomized clinical trial
Figure 4- Root mean square scores (RMS μV) of maximum volunteer contraction for each group, before and after treatments. A, anterior 
temporal muscles mean values; B, masseter muscles mean values.
ϯ represent significant differences among groups (P<0.05); * represent significant differences among time points (P<0.05).
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the self-perceived pain after one-month (P<.001). 
This was expected since the literature shows that the 
effectiveness of needling therapy in managing MMFP of 
the masticatory muscles does not necessarily depend 
on the needling type (dry or wet) or the injected 
substance, suggesting that the pain-reducing effect 
could be a consequence of the needle penetrating 
the skin.23 
Comparing the treatments, improvement in 
pain levels did not significantly differ between the 
acupuncture and BoNT-A groups (P>.05). However, 
both groups presented a significant reduction on pain 
compared to the SS group (P<.001). A previous study 
showed that BoNT-A injection and dry needling yield 
similar satisfactory therapeutic outcomes regarding 
pain relief in patients with MMFP.22 Nevertheless, to the 
best of our knowledge, this is the first study comparing 
BoNT-A to acupuncture (not to a conventional dry 
needling) and including a placebo group. Considering 
that both BoNT-A and acupuncture have specific pain 
relief mechanisms, (reduction in peripheral and central 
sensitization), this can explain the improvement 
in the results achieved in comparison to SS group. 
Furthermore, two factors should be emphasized to 
explain the self-reported pain reduction: firstly, the 
placebo effect, in which the expectations generated 
by receiving a therapeutic approach is able to 
modulate pain perception, a mechanism known as 
placebo analgesia;27 secondly, the natural course of 
MMFP, which is generally favorable and with varying 
symptoms.28,29
Patients with MMFP usually present reduced 
PPT.30 PPT may be the most sensitive measure to 
detect endogenous pain inhibitory mechanisms.31 
This measurement tests deep pain sensitivity, which 
is probably mediated by A-δ or C fibers; although 
pressure applied on the skin could reflect the pain 
sensitivity of both superficial and deep structures, the 
deep-tissue nociceptors mediate a major component of 
the pressure-induced pain during pressure algometry.32
Considering the PPT values for the masseter and 
anterior temporal muscles, the intragroup evaluation 
demonstrated that only BoNT-A group presented 
significantly higher PPT values (P<.001) at the follow-
up. This result can possibly be explained by the 
exclusive antinociceptive mechanism of the BoNT-A. 
After BoNT-A injection, there is a temporary inhibition 
of pain neurotransmitter release at the pain site, 
reducing peripheral sensitization. Additionally, due to 
the BoNT-A axonal transport by A-δ and/or C fibers to 
the central nervous system,33 there is an indirect or 
direct reduction of central sensitization, hyperalgesia, 
and allodynia occurs (features usually associated 
with chronic pain, such as refractory MFP), through 
the reduction of the peripheral nerve over-activity, 
resulting in an increased pain threshold.34 
Besides, some reasons might explain why 
acupuncture group did not show significant 
improvements in PPT: the short follow-up (one month), 
once a systematic review reported that dry needling 
treatments (such as acupuncture) may increase PPT 
immediately or until 12 weeks after the therapy;35 
secondly, the type of acupuncture performed in this 
study (manual) may have influenced, as literature 
suggest that electroacupuncture is a technique more 
suitable to improve PPT.36  
Between-groups comparisons on PPT values, 
BoNT-A treatment led to a higher increase in PPT values 
than in the SS group. This result is in accordance with 
a previous study that showed improvements of PPT 
after BoNT-A injection compared with the SS group 
in patients with MMFP.37 Notwithstanding, systematic 
reviews conclude that there is no consensus on the 
therapeutic benefits of BoNT-A on TMDs38 and that 
the efficacy-adverse effects ratio should be evaluated. 
Note that, in this study, BoNT-A improved all variables 
in a refractory MMFP population. These results 
reinforce that BoNT-A should not be the first option to 
MMFP treatment due to possible adverse effects, but 
it could be considered in patients that do not mitigate 
their pain with more conservative managements, fact 
that is corroborated by other studies.14,15,39
The EMG results for the masseter and anterior 
temporal muscles demonstrated that only patients 
treated with BoNT-A presented a significant reduction of 
the EMG activity one month after treatment (P<.001). 
Intergroup comparisons showed a significant decrease 
in muscle activity for both muscles in BoNT-A group 
when compared to acupuncture and SS groups. A 
reduction in EMG activity of masticatory muscles is 
expected after an intramuscular injection of BoNT-A 
once this toxin inhibits the release of acetylcholine 
at the neuromuscular junction of presynaptic 
motor neurons, reducing muscle activity.39 In fact, 
a temporary regional weakness is one of the most 
common adverse effects related to the use of BoNT-A 
in TMD treatment.19 A recent report also showed a 
significant reduction in maximum occlusal force in 
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the BoNT-A group compared to SS and no injection 
groups.40 
The occurrence and the intensity of these adverse 
effects are directly related to higher doses and 
repeated injections.19 In the present study, only a 
single injection of BoNT-A was used (30U in each 
masseter and 10U in each anterior temporal). Based 
on previous investigations,15 this dosage is able to 
reduce pain in MMFP patients, but it also allows the 
full recovery of muscle activity, which returned to 
normal EMG values after three months.15 Anyway, a 
reduction in the EMG activity of masticatory muscles 
is an adverse effect that must be considered; once 
acupuncture did not promote a significant change in 
EMG values, this could be considered an advantage 
of acupuncture over BoNT-A. Notably, the reduction 
of EMG values in BoNT-A groups is not responsible for 
decreasing subjective pain. Studies have demonstrated 
that BoNT-A presents an analgesic effect which is 
independent and precedes its neuromuscular effects. 
The EMG results in the acupuncture and BoNT-A 
groups confirms the disconnection between muscle 
electrical activity and muscle pain. Besides EMG 
reduction, patients receiving BoNT-A injections also 
reported adverse effects like edema and pain during 
injection, being the last also reported by the SS group. 
Conversely, self-reported adverse effects for the 
acupuncture group comprised itching and reddening 
of the skin, without pain symptoms nor edema.
These results suggest that all studied needling 
therapies (acupuncture, BoNT-A, and SS) are effective 
after one month of follow-up in reducing the self-
perceived pain in patients with refractory MMFP; 
and, that BoNT-A seems to be superior due to the 
improvement in PPT values. Nevertheless, caution is 
necessary when judging these findings, since some 
limitations should be considered. Selecting only 
women as the study population hinder our results 
to be generalized to male patients. However, it was 
necessary once MMFP is more prevalent in this gender. 
Even though the 1-month follow-up is a restricted 
time of evaluation, our main objective was to assess 
the immediate effects of the proposed treatments; 
however, studies considering longer periods of 
evaluation should be performed. Finally, the effects 
of the proposed therapies on the psychosocial status 
of myofascial TMD patients should be also evaluated, 
considering that psychosocial variables generally act 
as chronification factors for TMDs. 
Conclusion
After one month of follow-up, all therapies reduced 
the self-perceived pain in patients with MMFP. BoNT-A 
was not superior to acupuncture in pain reduction, 
but both were superior to SS; moreover, BoNT-A 
was the only treatment able to improve PPT values. 
However, only patients treated with BoNT-A reduced 
the EMG activity in the injected muscles which should 
be considered as an adverse effect.
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